InvestorsHub Logo
Followers 42
Posts 2609
Boards Moderated 0
Alias Born 08/24/2012

Re: None

Tuesday, 09/04/2012 10:26:33 PM

Tuesday, September 04, 2012 10:26:33 PM

Post# of 8779
Has anybody seen this new news , I see it was added 38min ago

Last update: 9/4/2012 9:45:00 PM
BEVERLY HILLS, Calif., Sept. 4, 2012 /PRNewswire via COMTEX/ -- Eaton Scientific Systems, Ltd. ("Eaton Scientific" or the "Company"), a wholly owned subsidiary of Pristine Solutions, Inc. (otcqb:PRTN) is pleased to announce that the Company has entered into an agreement with RoxSan Pharmacy Inc. to provide continued specialized compound prescription of Homatropine in a novel oral suspension ("Tropine 3") to support planned FDA compliant Clinical trial participants. Tropine 3 is a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women. Details regarding the multi-location multi-phase FDA compliant Tropine 3 clinic trials are expected to be finalized within the next few weeks.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.